Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia

被引:13
|
作者
Adam, Mohamed Hussein [1 ]
Mohamoud, Jamal Hasan [1 ]
Mohamood, Abdiaziz S. [2 ]
Mohamed, Ahmed A. [3 ]
Garba, Bashiru [4 ,5 ]
Dirie, Najib Isse [6 ]
机构
[1] SIMAD Univ, Fac Med & Hlth Sci, Dept Publ Hlth, Mogadishu 2526, Somalia
[2] SIMAD Univ, Fac Med & Hlth Sci, Dept Microbiol & Lab Sci, Mogadishu 2526, Somalia
[3] Somali Natl Univ, Fac Med & Surg, POB 15, Mogadishu, Somalia
[4] SIMAD Univ, Inst Med Res, Mogadishu 2526, Somalia
[5] Usmanu Danfodiyo Univ Sokoto, Fac Vet Med, Dept Vet Publ Hlth & Prevent Med, Sokoto 840212, Nigeria
[6] SIMAD Univ, Dr Sumait Hosp, Fac Med & Hlth Sci, Dept Urol, Mogadishu 2526, Somalia
关键词
COVID-19; seroprevalence; anti-SARS-CoV-2; antibodies; Mogadishu; Somalia;
D O I
10.3390/vaccines10020220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Only little is known about the true extent of COVID-19 in Somalia. The study aims to assess the seroprevalence of the COVID-19 pandemics in the Benadir region using SARS-CoV-2 antibodies and estimate the number of inhabitants infected with SARS-CoV-2. Population-based cross-sectional survey was conducted to measure the seroprevalence of antibodies against SARS-CoV-2 in the Benadir region (Mogadishu city). In the study, we enrolled 2500 Mogadishu city residents aged >= 18 years who did not receive the SARS-CoV-2 vaccine. The overall seroprevalence of IgG/IgM anti-SARS-CoV-2 antibodies was 44.8%. The seropositivity in females (56.6%) was higher than in males (46.2%). The trend in seropositivity increased with age; however, the variation was only significant in the age group 38-57 with an odds ratio and p-value of 4.11 (1.475-11.47), p = 0.007. Families with >5 members (47.2%) were more likely to test positive than those with <5 members (37%). Participants who reported COVID-19 symptoms during the pandemics or who had contact with COVID-19 patients had significantly increased IgG prevalence. Participants with larger families, individuals working in the public sector, and students showed significant seropositive results. Therefore, precautionary measures should be heightened for individuals working in the public sector.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola
    Sebastiao, Cruz S.
    Galangue, Manuela
    Gaston, Celestina
    Van-Dunen, Rui
    Quivinja, Joltim
    Lunbungululo, Emiliana
    Alfredo, Domingos
    Sozinho, Alberto
    Teixeira, Alice
    Manico, Eunice
    Machado, Deodete
    Mateus, Antonio
    David, Zinga
    Paixao, Joana
    Neto, Zoraima
    de Vasconcelos, Jocelyne Neto
    Morais, Joana
    [J]. BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [42] Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan
    Yang, Jin
    Ma, Libing
    Guo, Li
    Zhang, Ting
    Leng, Zhiwei
    Jia, Mengmeng
    Chen, Fangyuan
    Qi, Weiran
    Zhang, Xingxing
    Wang, Qing
    Yang, Yuan
    Feng, Luzhao
    Ren, Lili
    Yang, Weizhong
    Wang, Chen
    [J]. RESPIRATORY RESEARCH, 2022, 23 (01)
  • [43] Absence of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in stray cats
    Stranieri, Angelica
    Lauzi, Stefania
    Giordano, Alessia
    Galimberti, Luigi
    Ratti, Gabriele
    Decaro, Nicola
    Brioschi, Federica
    Lelli, Davide
    Gabba, Silvia
    Amarachi, Ndiana Linda
    Lorusso, Eleonora
    Moreno, Ana
    Trogu, Tiziana
    Paltrinieri, Saverio
    [J]. TRANSBOUNDARY AND EMERGING DISEASES, 2022, 69 (04) : 2089 - 2095
  • [44] Assessment of anti-SARS-CoV-2 antibodies level in convalescents plasma
    Skorek, Andrzej
    Jazwinska-Curyllo, Anna
    Romanowicz, Aleksandra
    Kwasniewski, Krzysztof
    Narozny, Waldemar
    Tretiakow, Dmitry
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (03) : 1130 - 1137
  • [46] Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
    Murewanhema, Grant
    Dzobo, Mathias
    Dzinamarira, Tafadzwa
    [J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2023, 30 (01) : 19 - 19
  • [47] Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy
    Buonomo, Antonio Riccardo
    Esposito, Nunzia
    Di Filippo, Isabella
    Saccone, Gabriele
    Pinchera, Biagio
    Scotto, Riccardo
    Bifulco, Giuseppe
    Gentile, Ivan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2022, 21 (09) : 1137 - 1141
  • [48] Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review
    Mink, Sylvia
    Reimann, Patrick
    Fraunberger, Peter
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2024, 62 (06) : 1029 - 1043
  • [49] About population tests to detect anti-SARS-CoV-2 antibodies
    Kantor, Isabel N.
    Ritacco, Viviana
    [J]. MEDICINA-BUENOS AIRES, 2020, 80 : 87 - 88
  • [50] Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers
    Johannesen, Caroline Klint
    St Martin, Gry
    Lendorf, Maria Elisabeth
    Gerred, Peter
    Fyfe, Alexander
    Paton, Robert S.
    Thompson, Craig
    Molsted, Stig
    Kann, Caroline Elisabeth
    Jensen, Claus Antonio
    Hansen, Cecilie Bo
    Lokkegaard, Ellen
    Christensen, Thomas Broe
    Simons, Peter
    Fischer, Thea K.
    [J]. DANISH MEDICAL JOURNAL, 2022, 69 (05):